AGIO Agios Pharmaceuticals Inc.

46.2
+0.03  (+0%)
Previous Close 46.17
Open 45.88
Price To Book 4.38
Market Cap 2,712,463,585
Shares 58,711,333
Volume 43,850
Short Ratio
Av. Daily Volume 577,594

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
AG-348 - Mitapivat
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 enrolment to be completed 2019.
AG-348 (ACTIVATE)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2020.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 data released May 15, 2019 met primary endpoint. Data to be presented at ESMO September 27-October 1, 2019.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 dose escalation data due 2H 2019.
AG-270
Solid tumors
Phase 3 trial to be initiated YE 2019.
Vorasidenib (AG-881)
Glioma
FDA Approval announced May 2, 2019.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 data presented at ASCO June 3, 2019, 2:15pm.
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma
Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib
IDH1 mutant newly diagnosed AML ineligible for standard therapies
Phase 1 updated data at ASCO June 3, 2019. 61% CR rate.
Ivosidenib and azacitidine ( Vidaza)
Newly diagnosed AML with an IDH1 mutation

Latest News

  1. See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.
  2. Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International
  3. Agios (AGIO) Catches Eye: Stock Jumps 5.4%
  4. Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?
  5. Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?
  6. Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019
  7. Life sciences VC firm Third Rock raises $770M in its largest round ever
  8. Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
  9. Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?
  10. Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
  11. The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
  12. Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight
  13. Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more
  14. Agios to Present Clinical Data from its IDH Program at ASCO
  15. Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients